The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company. In a statement, the company says the FDA's ...

Vanda Pharmaceuticals stands at a pivotal point, leveraging strong Fanapt growth and a robust late-stage pipeline for future expansion. VNDA's aggressive investment in commercial infrastructure has ...

The Khmer Boxing Federation (KBF) has appointed Nin Vanda as acting secretary-general, replacing Sien Sopheak, who submitted his resignation on September 19. The appointment was made at AEON Mall 3 on ...

The New York Islanders today announced a multi-year agreement with Vanda Pharmaceuticals, a global biopharmaceutical company, naming them the team’s exclusive jersey patch partner. This landmark ...

Vanda Pharmaceuticals and the FDA have agreed to lay down their swords, squashing years of legal disputes with an agreement that will see regulatory action on much of Vanda’s grievances. The ...

With a win in a D.C. appeals court, Vanda Pharmaceuticals has earned a point over the FDA in the yearslong face-off between the drugmaker and the drug regulator. Vanda has been fighting to market its ...

Vanda submitted its supplemental New Drug Application (sNDA) in October 2018 to market HETLIOZ ® to treat jet lag disorder. After the FDA substantially delayed resolving Vanda's request for a hearing ...

Vanda Pharmaceuticals is suing the FDA again, this time alleging the agency is unlawfully delaying a hearing to discuss the rejection of the biotech's stomach disorder drug last year. The FDA has ...

WASHINGTON - Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), currently valued at $273.5 million, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Bysanti™, a ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), a pharmaceutical company with a market capitalization of $290 million and impressive gross profit margins of 94%, disclosed in a recent SEC filing that the ...